Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) for its ulcerative colitis treatment, Mirikizumab.
Anebulo Pharmaceuticals is currently developing a new, first-of-its-kind drug, ANEB-001, intended to rapidly reverse the negative effects of acute cannabinoid intoxication (ACI) within one hour of administration. The treatment is a cannabinoid receptor...
uMotif is starting to reap the rewards of its patient first technology – that really does what it says on the tin, says the company’s CEO, Steve Rosenberg.
Dr. Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background,...
The US drug developer Nanopharmaceutics has teamed up with PrecisionLife in a strategic collaboration to accelerate the development of Nanopharmaceutics’ central nervous system (CNS) drug pipeline with precision medicine.
The world’s first anti-fibrotic small molecule inhibitor, discovered and designed by generative artificial intelligence (AI) has completed the first patient dose in a phase 2 clinical trial.
The Japanese company Shionogi has taken over the US biotech Qpex Biopharma for up to $140 million in a bid to expand its pipeline of antimicrobial drugs and boost its R&D muscle in infectious disease.
Everybody seems to be talking about artificial intelligence at the moment. Some are fascinated, others afraid and a few might worry for their jobs. However, for the pharmaceutical industry, it is said to be completely transforming the landscape.
Helmholtz Munich, part of Germany’s biggest research organization, the Helmholtz Association, alongside DDN, the world’s largest data storage company have been selected as a winner of the 2023 AI Breakthrough Awards, for best AI-based solution for life...
Sequana Medical has just announced additional data on safety, quality of life and survival from its North American alfapump study, called Poseidon which could signal an end to manual draining of ascites.
The escalation of a drug targeting tumors, by releasing active chemotherapy into the disease tissue, has had ‘remarkable’ results and also shown a reduction in side-effects.
Kelly Smeltzer loves processes, processes that work and save on waste and money. She has a particular interest in the excess production of pharmaceutical drugs and wastage, with 30 years of experience in supply chain management under her belt.
This time next week, the Boston Convention and Exhibition Center will be positively buzzing with a broad range of those in the pharmaceutical industry for the annual DIA global meeting.
A soft mist inhaler made by Resyca BV, a joint venture of Medspray Pharma BV and Recipharm AB, is being brought to patients with pulmonary arterial hypertension (PAH).
Positive phase 3 results from a trial studying fruquintinib, in patients with previously treated colorectal cancer (CRC) were announced by Hutchmed and Takeda on Friday (June 16).
CStone Pharmaceuticals' shares have risen after academic journal Nature Cancer published the clinical study results of its lung-cancer treatment sugemalimab.
Coordinating with Migraine and Headache Awareness Month (MHAM), this June, Pfizer has announced it is partnering with multi-award winning, singer and actress, Lady Gaga, who was diagnosed with migraine when she was 14.
Multinational pharmaceutical company, Gedeon Richter UK Ltd, announced this week that it has acquired full marketing and distribution rights to a contraceptive range.
The digital biomarkers company has partnered with Beacon Biosignlas, a computational neurodiagnostics company to launch a clinical trial investigate the integration of Beacon’s at-home electroencephalogram (EEG) into Koneksa’s neuroscience solution toolkit.
A collaboration will unlock Japan’s research and development (R&D) and boost the adoption of new technologies, experts in the Japanese pharmaceutical sector and a not-for-profit alliance say.
With the clinical trial landscape continuing to evolve and adapt, OSP took the opportunity to speak to CluePoints, a software company that provides sponsors and CROs a better way of detect and manage risks that may impact the outcome of clinical trials.
Mural Health is on a mission to make it as easy as possible for people to take part in clinical trials, the company will be heading to DIA Global in Boston where they hope to glean a meaningful understanding of the current landscape and hot topics.
A statistics manager at specialist biometrics contract research organization (CRO) Phastar, has been chosen to receive the DIA 2023 Global Inspire Award for Community Engagement.
The message mdgroup, an organization devoted to creating 'remarkable patient experiences through solutions for clinical trial recruitment, engagement, retention, and outcomes', is that its focus is on people not technology.
In a bid to address the high demand for clinical research talent, Advanced Clinical is hosting an innovation theater at DIA Global in Boston’s Convention and Exhibition Center.
Phastar is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services and will be providing a presentation and running a workshop to give delegates working...
CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients 'extract every drop of potential from the RBQM-driven interrogation of their own datasets'. It says it recognizes...
The US Food and Drug Administration (FDA) has announced this month (June) it is requesting feedback on draft recommendations and how they should be applied to increasingly diverse trial types and data sources.
Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
A new treatment approach to improve outcomes for patients with earlier stages of gastric and gastroesophageal junction cancers has had positive high-level results from a planned interim analysis of a phase 3 trial.
A cannabinoid receptor, that has shown potential as an effective treatment for chemotherapy induced peripheral neuropathy (CIPN) has been given approval for a phase 1 clinical trial by the Medicines and Healthcare Products Regulatory Agency (MRHA) and...
Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.
With generative AI continuing to create a buzz, OSP took the opportunity to speak to Indegene, a digital-first, life sciences commercialization company that helps biopharmaceutical, emerging biotech and medical device companies develop products. Talking...
Duchenne Muscular Dystrophy (DMD) is a genetic disorder that primarily affects males, caused by a mutation in the gene that encodes for a protein called dystrophin. This protein is crucial for the normal functioning of muscles, and its absence leads to...
A healthcare company on a mission to produce a multi-cancer early detection (MCED) test so patients have more chance of being cured, has produced 'exciting results' from a study.
Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.
Jim Murphy is Greenphire's CEO and leads the company's strategy and he says he is committed to fostering a culture of growth, innovation, excellence and employee satisfaction. Under his leadership, the company has expanded exponentially - in...
'Compelling and landmark' results will ‘fundamentally change’ the journey of patients with stage 2 and 3 early breast cancer, specifically those in need of new, well-tolerated options to prevent their cancer from coming back.
There is an urgent need for more targeted treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although first-line treatment has shown potential in a clinical study.
Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
